Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.51 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109340 | 0.85 | SIGMAR1 (0.50) | SIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL2131809 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1HPGDSIGMAR1DRD3 | |
| SCHEMBL976330 | 0.81 | KDM4E (0.57) | HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL669832 | 0.81 | THRB (0.61) | HSD17B10KDM4EALDH1A1HPGDMCL1 | |
| SCHEMBL485446 | 0.80 | KDM4E (0.47) | HSD17B10KDM4EALDH1A1HPGDMCL1 | |
| SCHEMBL8967049 | 0.80 | ALDH1A1 (0.60) | HSD17B10KDM4EALDH1A1HPGDDRD3 | |
| SCHEMBL13255537 | 0.79 | KDM4E (0.58) | HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL14052308 | 0.79 | LMNA (0.47) | SIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL2780177 | 0.79 | KDM4E (0.58) | HSD17B10KDM4EALDH1A1HPGDDRD3 | |
| SCHEMBL9978740 | 0.78 | MCL1 (0.60) | HSD17B10KDM4EALDH1A1HPGDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2575454-B1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| EP-2575454-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-0751939-B9 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0751939-B1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER LAMBERT CO (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0751939-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-01-08 | — | — | EP | disclosed |
| US-5498628-A | ANTIPSYCHOTIC, PSYCHOSTIMULATORY, ANTIAUTISTIC, ANTIDEPRESSANT AND HYPOTENSIVE AGENTS, PARKINSON'S DISEASE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-03-12 | — | — | US | disclosed |
| EP-0585116-B1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995025727-A1 | NAPHTHYLAMIDES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1995-09-28 | — | — | WO | disclosed |
| WO-1995010504-A1 | 2-(1-ALKOXY-2-NAPHTHALENYL)-PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-04-20 | — | — | WO | disclosed |
| US-5395835-A | Antipsychotic agents | WARNER-LAMBERT COMPANY (US) | 1995-03-07 | — | — | US | disclosed |
| US-5389684-A | Treats disorder of central nervous system | LILLY INDUSTRIES LIMITED (GB) | 1995-02-14 | — | — | US | disclosed |
| EP-0585116-A1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LIMITED (GB) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | HSD17B10 503/4885KDM4E 2710/4885ALDH1A1 1292/4885 |
| US-20130059860-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, OPRL1 | HSD17B10 3699/4885KDM4E 1827/4885ALDH1A1 2660/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HSD17B10 3409/4885KDM4E 1141/4885ALDH1A1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.